AbbVie Hepatitis C combo cures almost all patients in trials

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

AbbVie's (ABBV) three-drug combo for Hepatitis C cured 96.2-96.3% of patients in two Phase III trials, known as Sapphire-I and Sapphire-II.

The subjects in Sapphire II included those who hadn't responded well to previous treatment.

The regimen includes an Enanta (ENTA) inhibitor. (PR)

See more on Hepatitis C drug studies.